Abivax S.A.
No enriched coverage for $ABVX in the last 7 days.
No SEC Form 4 filings for $ABVX in the last 30 days.
See all $ABVX insider activity →Analysts initiated coverage on five companies: Goldman Sachs rated Abivax Buy with $155 PT, BTIG rated Amer Sports Buy with $42 PT, Morgan Stanley rated Coinbase Equal-Weight with $250 PT, Oppenheimer rated Aehr Test Outperform with $120 PT, and Piper Sandler rated Intel Neutral with $110 PT. All companies closed below their respective targets on Wednesday.
Analysts made several calls on Thursday, including Truist initiating Nebius with a Buy rating and $355 price target, Deutsche Bank initiating Clover Health with a Buy rating and $6 target, and Wells Fargo upgrading Synopsys and Yum Brands. Morgan Stanley initiated Revolution Medicine and upgraded TC Energy and DT Midstream. JPMorgan upgraded Meta to Overweight with an $820 target and reiterated Tesla as Neutral.
Abivax SA (ABVX) shares fell 44% to a worst-ever day after late-stage ulcerative colitis trial results for obefazimod showed ~51% clinical remission at week 44 vs 10.4% on placebo, but reports of non-melanoma skin cancers and other malignancies in older patients raised safety concerns. Jefferies cut its target to $90 from $160 and downgraded to Hold; Wedbush raised to Neutral with $90 target. Martin Shkreli said GLP-1 fears later proved unfounded.
Recent ABVX coverage spans financial news, regulation and technology.
Analyst initiation may lift sentiment and support price.
Buy rating could lift the biotech.
Efficacy looks strong, but the malignancy signal drives analyst downgrades and raises FDA approval and label-risk concerns.
Positive FDA pre-NDA alignment reduces filing uncertainty and supports the company’s stated end-2026 NDA timeline.
FDA feedback aligned the planned NDA submission strategy, supporting Abivax’s stated timeline to file by end of 2026.
AlphAI scores every news story that mentions ABVX with an AI model for sentiment and relevance, and aggregates insider trades from Abivax S.A.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Analysts initiated coverage on five companies: Goldman Sachs rated Abivax Buy with $155 PT, BTIG rated Amer Sports Buy with $42 PT, Morgan Stanley rated Coinbase Equal-Weight with $250 PT, Oppenheimer rated Aehr Test Outperform with $120 PT, and Piper Sandler rated Intel Neutral with $110 PT. All companies closed below their respective targets on Wednesday.
1 min readAnalysts made several calls on Thursday, including Truist initiating Nebius with a Buy rating and $355 price target, Deutsche Bank initiating Clover Health with a Buy rating and $6 target, and Wells Fargo upgrading Synopsys and Yum Brands. Morgan Stanley initiated Revolution Medicine and upgraded TC Energy and DT Midstream. JPMorgan upgraded Meta to Overweight with an $820 target and reiterated Tesla as Neutral.
3 min readAbivax SA (ABVX) shares fell 44% to a worst-ever day after late-stage ulcerative colitis trial results for obefazimod showed ~51% clinical remission at week 44 vs 10.4% on placebo, but reports of non-melanoma skin cancers and other malignancies in older patients raised safety concerns. Jefferies cut its target to $90 from $160 and downgraded to Hold; Wedbush raised to Neutral with $90 target. Martin Shkreli said GLP-1 fears later proved unfounded.
4 min readEQS-News: ABIVAX / Key word(s): Regulatory Admission Abivax Announces Positive Pre-NDA Interaction with the FDA for Obefazimod 30.07.2026 / 22:05 CET/CEST The issuer is solely responsible for the content of this announcement.
2 min readApple shares sink on disappointing September quarter sales outlook PARIS - Abivax SA (Euronext Paris:ABVX / NASDAQ:ABVX) announced today the completion of its pre-New Drug Application interaction with the U.S. Food and Drug Administration for obefazimod, a treatment for moderately to severely active ulcerative colitis in adults.
2 min readJefferies downgraded Abivax to ‘Hold’ from ‘Buy’ and slashed the price target to $90 from $160, a 30% potential downside from the stock’s closing price on Monday. Abivax said its late-stage trial to treat ulcerative colitis showed strong results. However, there was a small number of reported skin cancer cases and other malignancies in the higher-dose group.
4 min readAbivax SA (ABVX) said it expanded its commercial leadership team with four appointments covering marketing, patient services, sales and commercial operations, and market access/pricing. The company is preparing for potential U.S. commercialization of obefazimod (ABX464), with an NDA planned for Q4 2026, according to the press release.
3 min readBioPharma Dive roundup covers AstraZeneca’s eplontersen failure in a major heart disease study, boosting expectations for rival TTR amyloidosis drugs from Alnylam and BridgeBio. Other items include ARPA-H funding, GSK ending a neuroscience alliance with Alector, Vera Therapeutics’ FDA nod for IgA nephropathy, and Vertex’s $10B plan to buy Crinetics.
7 min readAbivax SA (ABVX) said it closed its previously announced underwritten public offering of 7.36M American Depositary Shares, including the underwriters’ option. Gross proceeds were about $920.0M (€807.4M) and estimated net proceeds about $874.1M (€767.1M). The company expects funding to support operations into Q4 2029.
2 min readAbivax shares rose nearly 6% in Paris after underwriters fully exercised a greenshoe option to buy 960,000 additional ADSs, raising total gross proceeds from its upsized public offering to $920m (€807m). The ADS offering priced at $125 on July 1. Jefferies upgraded Abivax to Buy, PT $158; company says cash runway extends into Q2 2029.
3 min read
